250 Royall Street Presented updated follow-up of the Phase 1/2 Alta Study assessing SB-525 in adult patients with severe hemophilia A in partnership with Pfizer at the 61st American Society of Hematology (ASH) annual meeting in December 2019. therapies for Alzheimer’s, Parkinson’s, neuromuscular and other neurodegenerative diseases. Sangamo Therapeutics, Inc is primarely in the business of biological products (no diagnostic substances). Please wait while we load the requested 10-K report or click the link below: https://last10k.com/sec-filings/report/1001233/000162828020002582/sgmo-20191231.htm, Sangamo Therapeutics, Inc provided additional information to their SEC Filing as exhibits, © 2012 – 2021 Last10K.com All Rights Reserved. This is Sangamo Therapeutics Inc. 2016 Annual Report Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements Filing year - Any - … [CDATA[> Completed the transfer of the investigational new drug application (IND) for 15 Dec 20. View all. Phase 3 lead-in study, which serves as the foundation of the Phase 3 registrational study. 8 Aug 18. Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Dec 7, 2020 Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10¹³ VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy BRISBANE - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights. This page shows recent SEC filings related to Sangamo BioSciences, Inc. ]]> SEC.report. 2018 Q3. by the newly announced Biogen collaboration, and will continue to look for additional synergistic partnership opportunities to advance our mission to bring innovative genomic medicines to patients and to create value for our shareholders.”. Diff. Create an account, Consolidated Balance Sheets (Parenthetical), Consolidated Statements Of Comprehensive Loss, Consolidated Statements Of Stockholders' Equity, Organization And Summary Of Significant Accounting Policies, Major Customers, Partnerships And Strategic Alliances, Organization And Summary Of Significant Accounting Policies (Policies), Organization And Summary Of Significant Accounting Policies (Tables), Major Customers, Partnerships And Strategic Alliances (Tables), Acquisition Of Acquisition Of Sangamo France (Tables), Quarterly Financial Data (Unaudited) (Tables), Organization And Summary Of Significant Accounting Policies - Additional Information (Detail), Organization And Summary Of Significant Accounting Policies - Revenues From Strategic Partnering Collaboration Agreements And Research Activity Grants (Detail), Organization And Summary Of Significant Accounting Policies - Reconciliation Of Cash And Cash Equivalents (Details), Organization And Summary Of Significant Accounting Policies - Impact Of Adoption Of Asc On Condensed Consolidated Balance Sheet (Detail), Fair Value Measurement - Summary Of Fair Value Measurements Of Cash Equivalents, Available-For-Sale Securities And Free Share Liability (Detail), Fair Value Measurement - Additional Information (Detail), Fair Value Measurement - Summary Of Estimated Fair Value Of Free Share Liability Assumptions (Detail), Marketable Securities - Summary Of Cash Equivalents And Available-For-Sale Securities (Detail), Marketable Securities - Summary Of Available-For-Sale Securities By Contractual Maturity (Detail), Marketable Securities - Additional Information (Detail), Major Customers, Partnerships And Strategic Alliances - Additional Information (Detail), Major Customers, Partnerships And Strategic Alliances - Revenues Recognized Under Agreement (Detail), Major Customers, Partnerships And Strategic Alliances - Agreement With Sigma-Aldrich Corporation - Additional Information (Detail), Major Customers, Partnerships And Strategic Alliances - Agreement With Dow Agrosciences In Plant Agriculture - Additional Information (Detail), Acquisition Of Sangamo France - Additional Information (Detail), Acquisition Of Sangamo France - Summary Of Estimated Fair Value Of Net Assets Acquired (Detail), Acquisition Of Sangamo France - Summary Of Non-Controlling Interest (Detail), Other Balance Sheet Details - Schedule Of Intangible Assets And Goodwill (Detail), Other Balance Sheet Details - Summary Of Accounts Payable And Accrued Liabilities (Detail), Commitments And Contingencies - Additional Information (Detail), Commitments And Contingencies - Summary Of Future Minimum Payments Under Contractual Obligations (Detail), Stockholders' Equity - Additional Information (Detail), Stockholders' Equity - Summary Of Stock Option Activity (Detail), Stockholders' Equity - Summary Of Restricted Stock Unit Activity (Detail), Stock-Based Compensation - Stock-Based Compensation Expense (Detail), Stock-Based Compensation - Additional Information (Detail), Stock-Based Compensation - Assumptions Used For Estimating Fair Value Of Employee Stock Options (Detail), Stock-Based Compensation - Weighted-Average Assumptions Used For Estimating Fair Value Of Espp Purchased Rights (Detail), Employee Benefit Plan - Additional Information (Detail), Income Taxes - Summary Of Domestic And Foreign Components Of Loss Before Income Taxes (Detail), Income Taxes - Summary Of Benefit For Income Taxes (Detail), Income Taxes - Additional Information (Detail), Income Taxes - Schedule Of Difference Between Benefit For Income Taxes And Federal Statutory Income Tax Rate (Detail), Income Taxes - Schedule Of Difference Between Benefit For Income Taxes And Federal Statutory Income Tax Rate, Additional Information (Detail), Income Taxes - Schedule Of Company's Deferred Tax Assets (Detail), Income Taxes - Summary Of Activity Related To Company's Unrecognized Tax Benefits (Detail), Quarterly Financial Data (Unaudited) - Summary Of Quarterly Financial Data (Detail), Exhibit 4.1: Instruments Defining The Rights Of Security Holders, Including Indentures, Exhibit 21.1: Subsidaries Of The Registrant, Exhibit 23.1: Consents Of Experts And Counsel, Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification, Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification, https://last10k.com/sec-filings/sgmo/0001628280-20-002582.htm. In addition, Biogen has exclusive rights to nominate The company's product … Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23rd Annual Meeting of … Sangamo BioSciences does not currently have any hardcopy reports on AnnualReports.com. About Sangamo Therapeutics ... including its most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. 8-K. Sangamo Therapeutics Reports … Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates Yahoo 11/04 17:45 ET -- Earnings Flash (SGMO) SANGAMO THERAPEUTICS Posts Q3 … Tabl e of Contents. Brisbane, California, February 28, 2020 – Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today However, despite this, analysts … Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported first quarter 2020 financial results and recent business highlights. a significant step in our mission to bring our genomic medicines to patients,” said Sandy Macrae, CEO of Sangamo. 10-Q. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2020 SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30171 68-0359556 (State or … It was originally known as Sangamo Biosciences, Inc. before changing names in 2017. Forward-looking statements contained in this announcement are made as of this date, and Sangamo … 7 Dec 20. T: 781-575-3951 Minimum 15 minutes delayed. Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights. As is evident from the statistics, the company’s shares have risen +22.27 percent over the past six months and at a 7.06% annual growth rate that is well below the industry average of 14.3%. Quarterly report. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K and its Current Report on Form 8-K as filed with the … new Date().getFullYear()>2010&&document.write(new Date().getFullYear());